Publications by authors named "Pavel I Novikov"

14 Publications

  • Page 1 of 1

Rheumatic diseases in intensive care unit patients with COVID-19.

Ann Rheum Dis 2021 02 20;80(2):e16. Epub 2020 May 20.

Vinogradov Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-217676DOI Listing
February 2021

What rheumatologist should know about Fabry disease.

Ann Rheum Dis 2020 06 30;79(6):e71. Epub 2019 Apr 30.

Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2019-215476DOI Listing
June 2020

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.

Ann Rheum Dis 2019 07 9;78(7):979-987. Epub 2019 Apr 9.

Internal Medicine and Rheumatology Department, Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Objective: To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical practice.

Methods: We performed a prospective study including patients with SSc from the European Scleroderma Trials and Research (EUSTAR) network treated with rituximab and matched with untreated patients with SSc. The main outcomes measures were adverse events, skin fibrosis improvement, lung fibrosis worsening and steroids use among propensity score-matched patients treated or not with rituximab.

Results: 254 patients were treated with rituximab, in 58% for lung and in 32% for skin involvement. After a median follow-up of 2 years, about 70% of the patients had no side effect. Comparison of treated patients with 9575 propensity-score matched patients showed that patients treated with rituximab were more likely to have skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; OR: 2.79 [1.47-5.32]; p=0.002). Treated patients did not have significantly different rates of decrease in forced vital capacity (FVC)>10% (OR: 1.03 [0.55-1.94]; p=0.93) nor in carbon monoxide diffusing capacity (DLCO) decrease. Patients having received rituximab were more prone to stop or decrease steroids (OR: 2.34 [1.56-3.53], p<0.0001). Patients treated concomitantly with mycophenolate mofetil had a trend for better outcomes as compared with patients receiving rituximab alone (delta FVC: 5.22 [0.83-9.62]; p=0.019 as compared with controls vs 3 [0.66-5.35]; p=0.012).

Conclusion: Rituximab use was associated with a good safety profile in this large SSc-cohort. Significant change was observed on skin fibrosis, but not on lung. However, the limitation is the observational design. The potential stabilisation of lung fibrosis by rituximab has to be addressed by a randomised trial.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214816DOI Listing
July 2019

Changing landscape of immunosuppression in ANCA-associated vasculitis.

Ann Rheum Dis 2020 05 12;79(5):e59. Epub 2019 Feb 12.

Department of Rheumatology, Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2019-215123DOI Listing
May 2020

Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine.

Ann Rheum Dis 2020 02 24;79(2):e19. Epub 2018 Nov 24.

Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214508DOI Listing
February 2020

Role of tubulointerstitial injury in ANCA-associated vasculitis is underestimated.

Ann Rheum Dis 2019 10 30;78(10):e111. Epub 2018 Jul 30.

Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214095DOI Listing
October 2019

Certolizumab pegol in the treatment of Takayasu arteritis.

Rheumatology (Oxford) 2018 12;57(12):2101-2105

Tareev Clinic of Internal Diseases, Sechenov First State Moscow Medical University, Moscow, Russia.

Objectives: Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA).

Methods: Ten females of reproductive age (18-35 years) with TA were treated with CZP (at a dose of 400 mg at weeks 0, 2 and 4 and at 200 mg every 2 weeks thereafter) for a median of 10 months (range 3-28). Prior to CZP administration all patients received glucocorticoids and ± MTX, CYC, AZA, HCQ, LEF or MMF. Six patients were previously treated with other biological anti-cytokine drugs. The National Institutes of Health criteria and the Indian Takayasu Clinical Activity Score 2010 were used to define disease activity.

Results: All patients rapidly responded to treatment with CZP and were able to taper prednisone and MTX doses. Treatment with CZP resulted in a significant decrease in median serum CRP levels and normalization of Indian Takayasu Clinical Activity Score 2010 score in 9 of 10 patients. Remission of systemic vasculitis was achieved in all patients. Seven patients maintained remission for at least 4 months, while one patient developed relapse after 2 years of CZP treatment. Side effects included mild infections (n = 5).

Conclusion: Our case series suggests that CZP may be an effective and steroid-sparing treatment option in patients with active TA even if they did not previously respond to other TNF inhibitors or tocilizumab.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key197DOI Listing
December 2018

Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy?

Ann Rheum Dis 2019 09 19;78(9):e99. Epub 2018 Jun 19.

Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-213873DOI Listing
September 2019

Tofacitinib in steroid-dependent relapsing polychondritis.

Ann Rheum Dis 2019 07 3;78(7):e72. Epub 2018 May 3.

Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-213554DOI Listing
July 2019

The role of temporal artery biopsy in patients with giant-cell arteritis is debated.

Ann Rheum Dis 2019 04 2;78(4):e31. Epub 2018 Mar 2.

Clinic of Nephrology, Internal and Occupational Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-213282DOI Listing
April 2019

Duration of maintenance therapy for ANCA-associated vasculitis: more questions than answers.

Ann Rheum Dis 2018 06 22;77(6):e29. Epub 2017 Jul 22.

Sechenov First Moscow State Medical University, Clinic of Nephrology, Internal and Occupational Diseases, Moscow, Russian Federation.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2017-211972DOI Listing
June 2018

ANCA-associated vasculitis: mission incomplete.

Ann Rheum Dis 2018 02 12;77(2):e8. Epub 2017 Jun 12.

Medical Center "K + 31", Moscow, Russian Federation.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2017-211773DOI Listing
February 2018

Eotaxin-3 as a Biomarker of Activity in Established Eosinophilic Granulomatosis with Polyangiitis.

J Rheumatol 2016 11;43(11):2082-2083

Clinic of Nephrology, Internal and Occupational Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160576DOI Listing
November 2016

Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience.

Rheumatol Int 2015 May 26;35(5):891-8. Epub 2014 Oct 26.

Clinic of Nephrology, Internal and Occupational Diseases, First Moscow State Medical University, Rossolimo, 11/5, Moscow, 119934, Russia.

The aim of our study was to study the changes in the clinical picture and outcomes of granulomatosis with polyangiitis (Wegener's) (GPA) over 40 years. Two hundred and forty-two consecutive patients with GPA were distributed into retrospective (1970-2003) and prospective (2004-2012) cohorts. Anti-neutrophil cytoplasmic antibodies were present in 82.6 % of patients. In 78.0 % of patients, diagnosis was confirmed histologically. We compared the clinical features of GPA and the incidence of the major and minor relapses and mortality in the two cohorts. The majority of patients in both cohorts had generalized GPA that involved upper respiratory tract (retrospective 89.5 % vs prospective 82.85 %), kidneys (60.5 vs 50.8 %) and lungs (64.0 vs 52.3 %). The total duration of follow-up in the retrospective and prospective cohorts was 468 and 397 patients-years, respectively. In the prospective cohort, we found trend to lower incidence of relapses (54.2 vs 66.2 per 100 patient-year; p = ns; odds ratio 0.82; 95 % CI 0.53-1.21) and significantly lower mortality (4.3 vs 7.9 per 100 patient-year; p = 0.04; odds ratio 0.54; 95 % CI 0.31-0.94). The leading causes of death in the retrospective cohort were lung disease (37.8 %), complications of immunosuppressive treatment (35.1 %) and kidney failure (13.5 %). In the prospective cohort, patients rarely died from terminal uraemia and pulmonary complications (0.0 and 17.6 %) while the proportion of cardiovascular events and complications of the immunosuppression as the causes of death increased (29.4 and 47.1 %). Modern treatment apparently reduced the incidence of relapses and mortality and modified the causes of death in the GPA patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-014-3154-4DOI Listing
May 2015
-->